ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lisinopril

Also written as “LP-003 Injection”, “lisinopril” and “LP-005 Injection”.

Its studies are mostly in Hypertension · Chronic Urticaria · Hemoglobinuria, Paroxysmal · Fasting · Rhinitis, Allergic, Seasonal, led by 10 companies.

Drug pageLisinopril: every studyMany companies study it; this page follows only the 39 they lead. All 79 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 5, 202539 company-led studies, 12 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Longbio Pharmaits history only149 open or runningphase 3since Dec 5, 2025Jun 27, 2023Nov 2026phase 1 · NCT06604949
GlaxoSmithKlineits history only60 open or runningphase 3since Apr 13, 2005Apr 13, 2005none ahead
Novartisits history only60 open or runningphase 4since Sep 12, 2005Sep 10, 2005none ahead
IPCA Laboratoriesits history only40 open or runningphase 1since Nov 5, 2012Nov 5, 2012none ahead
Longbio Pharma (Suzhou)33 open or runningphase 2since Apr 23, 2026Apr 23, 2026Jul 16, 2027phase 2 · NCT07816432
Par Healthits history only20 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
Ascension Healthits history only10 open or runningphase 4since Jan 2, 2018Jan 2, 2018none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Sep 1, 2013Sep 1, 2013none ahead
Intarcia Therapeuticsits history only10 open or runningphase 1since Dec 21, 2015Dec 21, 2015none ahead
Pharmtechnologyits history only10 open or runningphase 1since Sep 20, 2021Sep 20, 2021none ahead

Also a collaborator on its studies: PharmaKinetics Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Longbio Pharma (Suzhou) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 23, 2026First study: phase 2 study in PeriodontitisFirst studyNCT07603713 · 100 planned · China
  2. Aug 14, 2026Phase 2 study in Peanut HypersensitivityNCT07785063 · 80 planned · United States, Australia, Canada and more
  3. Sep 7, 2026Phase 2 study in Food HypersensitivityNCT07816432 · 12 planned · China

Ahead

  1. Nov 12, 2026Primary completion: phase 2 study in PeriodontitisNCT07603713
  2. Jul 16, 2027Primary completion: phase 2 study in Food HypersensitivityNCT07816432
  3. May 2029Primary completion: phase 2 study in Peanut HypersensitivityNCT07785063

TargetBeta

ACE →read by rule
“An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity”NCIt, by rule
“Angiotensin-converting enzyme inhibitor”ChEMBL 37, by rule

Studies

All 3 Longbio Pharma (Suzhou) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07816432Food Hypersensitivity · China2Not yet recruitingJul 16, 202712
NCT07785063Peanut Hypersensitivity · United States, Australia, Canada and more2Not yet recruitingMay 202980
NCT07603713Periodontitis · China2Not yet recruitingNov 12, 2026100

How it is read

Names in the registry

  • “Lisinopril”, 10 entries
  • “LP-003 Injection”, 5 entries
  • “lisinopril”, 5 entries
  • “LP-005 Injection”, 4 entries
  • “LP-003”, 2 entries

Codes read as this program: LP003, LP005, LP001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.